Up | AC
Home Page
Food and
Drug Administration
Endocrinologic
and Metabolic Drugs Advisory Committee
June 13,
2007
BRIEFING INFORMATION
NDA 21-888
ZIMULTI®
(rimonabant) – Sanofi-Aventis
Disclaimer
The statements contained in this
document(s) are those of the product's sponsor, not FDA, and FDA does not
necessarily agree with the sponsor's statements. FDA has not made a final
determination about the safety or effectiveness of the product described in
this document.
Sanofi-Aventis Briefing Document (pdf) (html)
FDA
Disclaimer
Portions of this document have been determined to be exempt from
disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the screen or on the
printed page.
FDA Briefing Document (pdf)
Bibliography Addendum (pdf)